Standout Papers

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Resu... 2020 2026 2022 2024393
  1. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial (2020)
    Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology
  2. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial (2020)
    Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Self-Cascaded Pyroptosis-STING Initiators for Catalytic Metalloimmunotherapy
2025 Standout
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
3 intermediate papers

Works of Tien Hoang being referenced

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
2022
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
2013
and 1 more

Author Peers

Author Last Decade Papers Cites
Tien Hoang 1740 1410 408 65 2.3k
Vincent van der Noort 1203 1387 253 128 2.4k
Hideki Kimura 1023 1378 772 66 2.2k
Craig H. Reynolds 1270 1316 462 57 2.0k
Jessica Menis 1098 1045 362 75 1.8k
Esma Saâda-Bouzid 1325 929 282 87 1.9k
Michael Millward 1718 1123 1127 43 2.9k
Sreenivasa Nattam 1842 1030 755 42 2.6k
G. Robinet 2038 2244 519 109 3.0k
Yuka Fujita 1176 1228 316 74 1.8k
Penelope A. Bradbury 1055 1088 585 110 1.9k

All Works

Loading papers...

Rankless by CCL
2026